Company: CERO
Filing Date: 2025-06-16
Form Type: 424B3
Source: 0001213900-25-054769
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-16
Form: 424B3
Chunk 4
---
 the full text of
the certificate of amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and is incorporated herein by reference.

Item 8.01 Other Events.

On June
11, 2025, the Company issued a press release announcing the Reverse Stock Split and other related information. A copy of the press release
is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

<div align='center'>1</div>

Cautionary Note Regarding Forward Looking Statements

This communication
contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding
the Company’s expectations about the effects of the Reverse Stock Split, including the trading of the Company’s common stock
on The Nasdaq Capital Market following the Reverse Stock Split. These statements constitute projections, forecasts and forward-looking
statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical
or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “strive,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. When the Company discusses its strategies or plans, it is making projections, forecasts or forward-looking
statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, the Company’s
management.

Actual
results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual
results to differ include, among others: outcomes of the Company’s planned clinical trials and studies may not be favorable; that
one or more of the Company’s product candidate programs will not proceed as planned for technical, scientific or commercial reasons;
availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical
trials or to market a products; uncertainties regarding intellection property protection; and those set forth in the Company’s filings
with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and the latest quarterly
filings, and the documents